ロード中...
Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients
The role of IgE autoantibodies has been demonstrated in the pathogenesis of bullous pemphigoid for many years. Recently, omalizumab (OMZ), a humanized monoclonal anti-IgE antibody that depletes total serum IgE, has been used off-label in a few case series of bullous pemphigoids demonstrating a rapid...
保存先:
主要な著者: | , , , , , , , , |
---|---|
フォーマット: | Artigo |
言語: | Inglês |
出版事項: |
Frontiers Media S.A.
2022-04-01
|
シリーズ: | Frontiers in Immunology |
主題: | |
オンライン・アクセス: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.874108/full |
タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|